ALPMY News and Press, Astellas Pharma Inc. ADR From 09/30/22

The European Medicines Agency (EMA) accepted to review Astellas Pharma's ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) application seeking approval of oral drug fezolinetant to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, commonly called hot...

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant PR Newswire If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause ...

Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts PR Newswire Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise fo...

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer PR Newswire – Results demonstrated a 64.5%...

Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) reported data from a phase 3 trial of its oral medicine fezolinetant to treat moderate to severe vasomotor symptoms (VMS) associated with menopause in women in mainland China. The company said the main goal of the...

Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China PR Newswire Clinical trial evaluated the safety and tolerability of 30 mg dose for the treatment of vasomotor symptoms (VMS) associated with menopause TOK...

Summary Twist Bioscience share price has fallen by 50% since the beginning of 2022. Management thinks DNA data storage could be $2 billion market for the company, aided by early mover advantage and investment in IP. Twist Bioscience recently raised full-year revenue guidance, ...

Summary Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has...

Astellas Pharma Inc. (OTC:ALPMY) said today that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for Fezolinetant, an oral, non-hormonal compound that is being tested to treat moderate to severe vasomotor symptoms (VMS) caused ...

The U.S. Food and Drug Administration (FDA) accepted to review Astellas Pharma's ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) application seeking approval of fezolinetant to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. The FDA is expected to make ...